COMMUNIQUÉS West-GlobeNewswire

Treace to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
24/07/2025
MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on [...]
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
24/07/2025
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
24/07/2025
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to [...]
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative [...]
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
24/07/2025
Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference ® (AAIC) 2025 Conference call and webcast to be held [...]
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
24/07/2025
CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and [...]
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24/07/2025
ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of [...]
The Ensign Group Reports Second Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance
24/07/2025
Conference Call and Webcast scheduled for tomorrow, July 25, 2025 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign (TM [...]
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
24/07/2025
Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs [...]
CooperCompanies Announces Release Date for Third Quarter 2025
24/07/2025
SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at [...]
Rakovina Therapeutics Announces Warrant Exercise Incentive Program
24/07/2025
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “ Company ” or “ Rakovina ”) a biopharmaceutical company advancing cancer therapies through artificial [...]
Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow
24/07/2025
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Algernon Announces Closing of the Private Placement Financing
24/07/2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: [...]
Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
24/07/2025
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
Natural Brain Support Without the Crash: Lives Potions Introduces Plant-Based Cognitive Enhancement
24/07/2025
This Herbal Brain Booster supports short-term focus and long-term brain health, offering calm, clean mental energy without jitters or burnout Brooklyn, NY, July 24, 2025 (GLOBE NEWSWIRE) -- Lives Potions is making waves [...]
Guerbet : Chiffre d’affaires du 1er semestre 2025
24/07/2025
Chiffre d’affaires du 1 er semestre 2025 Activité semestrielle Un chiffre d’affaires à mi-exercice de 387,8 M€, marquant un repli de 5,4% à TCC 1 et périmètre comparable 2 très largement dû à la baisse d’activité en [...]

Pages